YC137

YC137 is a potent Bcl-2 antagonist with Kis of 1.3 μM and >100 μM for Bcl-2 and Bcl-xL when assayed in Bis-Tris buffer, respectively. YC137 inhibits the binding of the Bid BH3 peptide to Bcl-2, thus disrupting an interaction essential for the antiapoptotic activity of Bcl-2. YC137 selectively induces apoptosis of Bcl-2-dependent cells. YC137 has the potential for breast cancer research[1][2].

Product Specifications

CAS Number

[810659-53-1]

UNSPSC

12352005

Target

Apoptosis; Bcl-2 Family

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/yc137.html

Smiles

CSCC[C@@H](C(OC1=CC=C(NC2=NC(C3=O)=C(C(C4=C3C=CC=C4)=O)S2)C=C1)=O)NC(OC)=O

Molecular Formula

C24H21N3O6S2

Molecular Weight

511.57

References & Citations

[1]YC137 was solubilized at 10 mmol/L in dimethylsulfoxide and kept at 20°C in the dark until use.|[2]Rie Nishi, et al. Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line. Cancer Sci. 2013 Apr;104 (4) :502-7.